@FiercePharma: ICYMI yesterday: FDA updates label for Novartis' MS pill Gilenya after reports of brain infection. Article | Follow @FiercePharma
@EricPFierce: Aprecia is building $25M plant where it will do 3D printing of drugs. FiercePharmaManufacturing article | Follow @EricPFierce
@CarlyHFierce: Perrigo CEO: Think Mylan's buyout will come easily? Think again. More | Follow @CarlyHFierce
> India has put off free trade talks with Europe after the European Union refused to lift a ban on the sale of about 700 drugs. Report
> Billionaire hedge funder Daniel Loeb asked for two seats on the board of Baxter International ($BAX), saying he could help find a new CEO for the company. Report
> The rate of cancer survival is improving in England, but still lags other countries with similar healthcare systems. Report
> England's cost-effectiveness watchdog said it might consider making AstraZeneca's ($AZN) new drug Lynparza available to ovarian cancer patients who have already undergone three rounds of chemo. Report
Medical Device News
@FierceMedDev: DNAnexus teams up with FDA for Precision Medicine cloud-based genomics platform. More from FierceDiagnostics | Follow @FierceMedDev
@VarunSaxena2: ICYMI: Intuitive awards grants to support training of its da Vinci robot using virtual reality. Article | Follow @VarunSaxena2
@EmilyWFierce: A little news on CEO compensation. More from the WSJ | Follow @EmilyWFierce
> Global tech organization reveals new system for blood glucose monitoring devices. Story
> Medtronic recalls CoreValve TAVR component due to presence of particulate matter. News
> Miniature surgical robot startup gets $11M to assess feasibility in colon resection. Article
Biotech News
@FierceBiotech: Scripps team finds a drug that fights addiction by eliminating memories. FierceBiotechResearch story | Follow @FierceBiotech
@JohnCFierce: What's + PhII data from a small allergy study worth? Aimmune bags $160M IPO as the market continues to embrace bio. Article | Follow @JohnCFierce
@DamianFierce: "IPO (n.): An acronym for 'initial public offering' that neglects to mention the taking." More | Follow @DamianFierce
> Epizyme parts ways with its CEO ahead of big Phase II cancer bet. Item
> Eyeing first profits, Tillman Gerngross's Avitide nabs one last VC round. Report
> AstraZeneca buys a new immuno-oncology weapon in $510M Heptares deal. Article
Vaccines News
> U.K's Prokarium scores $585,000 for oral chlamydia vaccine. Report
> State vaccination laws impact outbreak rates, study finds. Item
> Merck Ebola vaccine posts 100% efficacy in PhIII. More
> Novavax reports PhII success for quadrivalent seasonal flu vax. Story
> CSL completes purchase of Novartis' flu vaccine business. Article
CRO News
> Quintiles' $950M IPO keeps on giving for PE backers. Report
> Icon gets in on the ground floor with a Novartis-backed biotech upstart. More
> Patheon signs up to manufacture Flexion's lead drug. Item
> Parexel returns to growth after a shaky quarter. Story
> INC raises its 2015 expectations after another strong quarter. Article
Pharma Manufacturing News
> India, mad over EU ban on drugs, postpones trade talks. Item
> AMRI's expansion binge pays off for CMO. Story
> FDA warning letter smacks Indian lab for repeated shortcomings. More
> French regulator found 30 cases of mold contamination in biotech plant. Report
> GSK moves foward in Bangalore with new Indian plant. Article
Pharma Asia News
> India defers EU trade talks as ban on GVK-tested drugs rankles. Item
> China-focused Mabtech licenses four mAB candidates to Sorrento. More
> BeiGene receives first China trial approval nod for BGB-283. Story
> GSK rehires former China government affairs director Shi. Report
> AstraZeneca stands out again in China, hails AZD9291 in Japan. Article
And Finally... In offering Actavis financing for its purchase of Allergan ($AGN) last year, Japan's Mizhuo Financial Group illustrated its Wall Street ambitions. Report